Greenland vs Lebanon: Tuberculosis patients living with HIV receiving antiretroviral therapy
Greenland
3 patients
in 2021
Lebanon
3 patients
in 2021
Greenland rank
117th
Lebanon rank
117th
Tuberculosis patients living with HIV receiving antiretroviral therapy over time
- Greenland
- Lebanon
How they compare
Greenland currently reports 3 patients against 3 patients in Lebanon, a difference of 0 patients.
Across all 8 years both countries report, Lebanon has been ahead every year.
Greenland ranks 117th and Lebanon ranks 117th of 183 countries.
Lebanon has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Greenland | Lebanon | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.5 patients | 17.5 patients | 17 patients | Lebanon |
| 2010s | 0.4 patients | 3.6 patients | 3.2 patients | Lebanon |
| 2020s | 3 patients | 3 patients | 0 patients | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients living with hiv receiving antiretroviral therapy, Greenland or Lebanon?
- Greenland, at 3 patients against 3 patients in Lebanon as of 2021.
- What is the difference in tuberculosis patients living with hiv receiving antiretroviral therapy between Greenland and Lebanon?
- 0 patients, with Greenland ahead.
- How many years of comparable data are there for Greenland and Lebanon?
- 8 years are reported by both, from 2008 to 2021.
- How do Greenland and Lebanon rank globally for tuberculosis patients living with hiv receiving antiretroviral therapy?
- Greenland ranks 117th and Lebanon ranks 117th of 183 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of tuberculosis patients who are living with HIV and receiving antiretroviral therapy.